Summating Potential/Action Potential Area Ratio Best for ID'ing Meniere Disease
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 3, 2024 -- Compared with summating potential (SP) amplitude value by tone burst stimulation, SP/action potential (AP) area ratio by click stimulus has higher sensitivity and specificity for detecting Meniere disease (MD), according to a study published online Feb. 28 in Otolaryngology-Head and Neck Surgery.
Naif Bawazeer, M.D., from the University of Montreal, and colleagues conducted a retrospective comparative study involving 95 patients with MD who met the inclusion criteria for electrocochleography (ECochG) testing in a tertiary care center. The SP amplitude value performed by a transtympanic electrode and a click stimulus (TT-CS), the SP/AP area under the curve ratio performed by an extratympanic electrode and a click stimulus (ET-CS), and the SP amplitude value performed by a transtympanic electrode and tone burst stimulus (TT-TBS) were compared.
The researchers found that sensitivity and specificity were 88.5 and 70.0 percent, respectively, for the SP/AP area ratio by a TT-CS compared with 60.0 and 55.6 percent, respectively, for the SP amplitude value by a TT-TBS. For detecting MD, the SP/AP area ratio by TT-CS was significantly better than SP amplitude value by TT-TBS. No difference was seen between the SP/AP area ratio by ET-CS and SP amplitude value by a TT-TBS.
"ECochG would be extremely useful in the diagnosis of MD if we use the SP/AP area ratio," the authors write. "Larger prospective studies with normal healthy subjects are recommended to generalize these finding."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.